Review

pei nanocomplex (Affibody)

Name: pei nanocomplex
Brand: Affibody
Rating: 90 (1 reviews)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Affibody pei nanocomplex

Schematic showing the cell specific silencing strategy mediated by <t>PEI</t> <t>nanocomplex</t> fabricated with aptamer and siRNA. PEI nanoparticle is formed using sodium citrate as charge stabilizer, followed by the addition of siRNA and EpCAM aptamer to form the PEI-Apt-siRNA complex. This complex guided by the aptamer, binds to the EpCAM positive cells and delivers the siRNA in the cytoplasm resulting in target gene silencing and inhibition of cellular function pertained to it.

Pei Nanocomplex, supplied by Affibody, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pei nanocomplex/product/Affibody
Average 90 stars, based on 1 article reviews

pei nanocomplex - by Bioz Stars, 2026-03

90/100 stars

Images

1) Product Images from "EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex"

Article Title: EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex

Journal: Journal of Biomedical Science

doi: 10.1186/s12929-014-0108-9

Schematic showing the cell specific silencing strategy mediated by PEI nanocomplex fabricated with aptamer and siRNA. PEI nanoparticle is formed using sodium citrate as charge stabilizer, followed by the addition of siRNA and EpCAM aptamer to form the PEI-Apt-siRNA complex. This complex guided by the aptamer, binds to the EpCAM positive cells and delivers the siRNA in the cytoplasm resulting in target gene silencing and inhibition of cellular function pertained to it.

Figure Legend Snippet: Schematic showing the cell specific silencing strategy mediated by PEI nanocomplex fabricated with aptamer and siRNA. PEI nanoparticle is formed using sodium citrate as charge stabilizer, followed by the addition of siRNA and EpCAM aptamer to form the PEI-Apt-siRNA complex. This complex guided by the aptamer, binds to the EpCAM positive cells and delivers the siRNA in the cytoplasm resulting in target gene silencing and inhibition of cellular function pertained to it.

Techniques Used: Inhibition, Cell Function Assay

Effect of citrate on the nanocomplex size, charge and characterization of the nanocomplex. Graph showing the hydrodynamic sizes (A) and surface charge (B) of PEI: citrate nanocomplexes formed using different ratio of PEI to citrate measured using zetasizer. C . Titration of different concentration of aptamer and siRNA was carried out and loaded onto 2% agarose gel with ethidium bromide and checked for the retention of the PEI complex on the wells. Lane 3 shows 200nM of aptamer and 200nM of siRNA is required to saturate 0.3μgs of PEI and the next highest concentration of 300nM of aptamer & siRNA respectively had some amount of free siRNA and aptamer (lane 4). Lane 5 & 6 indicates free aptamer and siRNA indicated with red and black arrow respectively. On the right, histogram plot showing Particle size distribution of the PEI-Apt-siRNA nanocomplex. D . Histogram overlay plot showing the percent number distribution of the PEI nanocore alone and PEI-nanocomplex with aptamer and siRNA (hydrodynamic diameter in nm) measured using zetasizer. E . Graph showing the total counts of representative zeta-potential (mV) of the PEI nanocore and the PEI-Apt-siEp nanocomplex. F . TEM images of the PEI nanocomplex left panel showing the uniformity of particle distribution and histogram showing distinct particles with a spherical shape (G) . H . Graph showing the percentage cell proliferation upon treating with different concentration from 0.1 to 3 μg/mL of PEI on MCF-7 and WERI-Rb1 cell line till 48 h. Inhibitory effect of PEI on the cell proliferation and mitrochondrial activity was assessed by MTT assay.

Figure Legend Snippet: Effect of citrate on the nanocomplex size, charge and characterization of the nanocomplex. Graph showing the hydrodynamic sizes (A) and surface charge (B) of PEI: citrate nanocomplexes formed using different ratio of PEI to citrate measured using zetasizer. C . Titration of different concentration of aptamer and siRNA was carried out and loaded onto 2% agarose gel with ethidium bromide and checked for the retention of the PEI complex on the wells. Lane 3 shows 200nM of aptamer and 200nM of siRNA is required to saturate 0.3μgs of PEI and the next highest concentration of 300nM of aptamer & siRNA respectively had some amount of free siRNA and aptamer (lane 4). Lane 5 & 6 indicates free aptamer and siRNA indicated with red and black arrow respectively. On the right, histogram plot showing Particle size distribution of the PEI-Apt-siRNA nanocomplex. D . Histogram overlay plot showing the percent number distribution of the PEI nanocore alone and PEI-nanocomplex with aptamer and siRNA (hydrodynamic diameter in nm) measured using zetasizer. E . Graph showing the total counts of representative zeta-potential (mV) of the PEI nanocore and the PEI-Apt-siEp nanocomplex. F . TEM images of the PEI nanocomplex left panel showing the uniformity of particle distribution and histogram showing distinct particles with a spherical shape (G) . H . Graph showing the percentage cell proliferation upon treating with different concentration from 0.1 to 3 μg/mL of PEI on MCF-7 and WERI-Rb1 cell line till 48 h. Inhibitory effect of PEI on the cell proliferation and mitrochondrial activity was assessed by MTT assay.

Techniques Used: Titration, Concentration Assay, Agarose Gel Electrophoresis, Zeta Potential Analyzer, Activity Assay, MTT Assay

Cell Uptake of the PEI nanocomplex by MCF-7 and WERI-Rb1 cells. The fabricated PEI complexes and free aptamer were added to MCF-7 cells (upper panel A - E ), WERI-Rb1 cells (lower panel A - E ) and incubated for their uptake at 37°C for 4 h followed DAPI counterstaining and microscopic evaluation. Images were taken at 40× using AxioObserver fluorescent microscope. Legend on the top of phase image represents the aptamer or nanocomplex added to the respective panels.

Figure Legend Snippet: Cell Uptake of the PEI nanocomplex by MCF-7 and WERI-Rb1 cells. The fabricated PEI complexes and free aptamer were added to MCF-7 cells (upper panel A - E ), WERI-Rb1 cells (lower panel A - E ) and incubated for their uptake at 37°C for 4 h followed DAPI counterstaining and microscopic evaluation. Images were taken at 40× using AxioObserver fluorescent microscope. Legend on the top of phase image represents the aptamer or nanocomplex added to the respective panels.

Techniques Used: Incubation, Microscopy

Image Search Results

Characteristics of N -Ac- l -Leu-PEI nanoparticles. The N -Ac- l -Leu-PEI/miR-34a nanocomplexes were prepared at different mass ratios for (A) agarose gel retardation assays, (B) particle size assays and (C) zeta potential assays, (D) TEM micrographs of N -Ac- l -Leu-PEI/miR-34a nanocomplexes with a mass ratio of 4 : 1. Data represent the means ± SD of three independent experiments.

Journal: RSC Advances

Article Title: N -Acetyl- l -leucine-polyethylenimine-mediated miR-34a delivery improves osteogenesis and bone formation in vitro and in vivo

doi: 10.1039/c7ra12548h

Figure Lengend Snippet: Characteristics of N -Ac- l -Leu-PEI nanoparticles. The N -Ac- l -Leu-PEI/miR-34a nanocomplexes were prepared at different mass ratios for (A) agarose gel retardation assays, (B) particle size assays and (C) zeta potential assays, (D) TEM micrographs of N -Ac- l -Leu-PEI/miR-34a nanocomplexes with a mass ratio of 4 : 1. Data represent the means ± SD of three independent experiments.

Article Snippet: The particle sizes and zeta potentials of N -Ac- l -Leu-PEI/miR-34a nanocomplexes were examined using a Zetasizer Nano ZS90 (Malvern Instruments, Malvern, UK).

Techniques: Agarose Gel Electrophoresis, Zeta Potential Analyzer

Transfection efficiency of N -Ac- l -Leu-PEI/miR-34a. (A) Images of FAM-miR-34a-positive MG63 cells under fluorescent light and FCM. Scale bar: 100 μm. (a) Blank, (b) FAM-miR-34a, (c) Lipofectamine 2000/FAM-miR-34a, (d) N -Ac- l -Leu-PEI/FAM-miR-34a with a w/w ratio of 2, (e) N -Ac- l -Leu-PEI/FAM-miR-34a with a w/w ratio of 4, (f) N -Ac- l -Leu-PEI/FAM-miR-34a with a w/w ratio of 6. (B) Real time PCR assay to examine the expression level of miR-34a in the 72 h after transfection. Data represent the means ± SD of three independent experiments. * P < 0.05 vs. the blank group by paired t -test, # P < 0.05 vs. the Lipofectamine 2000/FAM-miR-34a group by paired t -test.

Journal: RSC Advances

Article Title: N -Acetyl- l -leucine-polyethylenimine-mediated miR-34a delivery improves osteogenesis and bone formation in vitro and in vivo

doi: 10.1039/c7ra12548h

Figure Lengend Snippet: Transfection efficiency of N -Ac- l -Leu-PEI/miR-34a. (A) Images of FAM-miR-34a-positive MG63 cells under fluorescent light and FCM. Scale bar: 100 μm. (a) Blank, (b) FAM-miR-34a, (c) Lipofectamine 2000/FAM-miR-34a, (d) N -Ac- l -Leu-PEI/FAM-miR-34a with a w/w ratio of 2, (e) N -Ac- l -Leu-PEI/FAM-miR-34a with a w/w ratio of 4, (f) N -Ac- l -Leu-PEI/FAM-miR-34a with a w/w ratio of 6. (B) Real time PCR assay to examine the expression level of miR-34a in the 72 h after transfection. Data represent the means ± SD of three independent experiments. * P < 0.05 vs. the blank group by paired t -test, # P < 0.05 vs. the Lipofectamine 2000/FAM-miR-34a group by paired t -test.

Article Snippet: The particle sizes and zeta potentials of N -Ac- l -Leu-PEI/miR-34a nanocomplexes were examined using a Zetasizer Nano ZS90 (Malvern Instruments, Malvern, UK).

Techniques: Transfection, Real-time Polymerase Chain Reaction, Expressing

Cytotoxicity of N -Ac- l -Leu-PEI in MG63 cells. (A) Cell viability of MG63 cells treated with the PEI25K/miR-34a nanocomplex (wt/wt, 4 : 1), N -Ac- l -Leu-PEI/miR-34a nanocomplex (wt/wt, 4 : 1) or Lipofectamine 2000/miR-34a for 24, 48 and 72 h. (B) Apoptosis of MG63 cells treated with the PEI25K/miR-34a nanocomplex (wt/wt, 4 : 1), N -Ac- l -Leu-PEI/miR-34a nanocomplex (wt/wt, 4 : 1) or Lipofectamine 2000/miR-34a for 72 h. Data represent the means ± SD of three independent experiments. * P < 0.05 vs. the PEI25K/miR-34a group by paired t -test.

Journal: RSC Advances

Article Title: N -Acetyl- l -leucine-polyethylenimine-mediated miR-34a delivery improves osteogenesis and bone formation in vitro and in vivo

doi: 10.1039/c7ra12548h

Figure Lengend Snippet: Cytotoxicity of N -Ac- l -Leu-PEI in MG63 cells. (A) Cell viability of MG63 cells treated with the PEI25K/miR-34a nanocomplex (wt/wt, 4 : 1), N -Ac- l -Leu-PEI/miR-34a nanocomplex (wt/wt, 4 : 1) or Lipofectamine 2000/miR-34a for 24, 48 and 72 h. (B) Apoptosis of MG63 cells treated with the PEI25K/miR-34a nanocomplex (wt/wt, 4 : 1), N -Ac- l -Leu-PEI/miR-34a nanocomplex (wt/wt, 4 : 1) or Lipofectamine 2000/miR-34a for 72 h. Data represent the means ± SD of three independent experiments. * P < 0.05 vs. the PEI25K/miR-34a group by paired t -test.

Article Snippet: The particle sizes and zeta potentials of N -Ac- l -Leu-PEI/miR-34a nanocomplexes were examined using a Zetasizer Nano ZS90 (Malvern Instruments, Malvern, UK).

Techniques:

Cytotoxicity of N -Ac- l -Leu-PEI in MG63 cells. Live/dead cell viability assay of MG63 cells treated with the PEI25K/miR-34a nanocomplex (wt/wt, 4 : 1), N -Ac- l -Leu-PEI/miR-34a nanocomplex (wt/wt, 4 : 1) or Lipofectamine 2000/miR-34a for 72 h.

Journal: RSC Advances

Article Title: N -Acetyl- l -leucine-polyethylenimine-mediated miR-34a delivery improves osteogenesis and bone formation in vitro and in vivo

doi: 10.1039/c7ra12548h

Figure Lengend Snippet: Cytotoxicity of N -Ac- l -Leu-PEI in MG63 cells. Live/dead cell viability assay of MG63 cells treated with the PEI25K/miR-34a nanocomplex (wt/wt, 4 : 1), N -Ac- l -Leu-PEI/miR-34a nanocomplex (wt/wt, 4 : 1) or Lipofectamine 2000/miR-34a for 72 h.

Article Snippet: The particle sizes and zeta potentials of N -Ac- l -Leu-PEI/miR-34a nanocomplexes were examined using a Zetasizer Nano ZS90 (Malvern Instruments, Malvern, UK).

Techniques: Viability Assay

Osteogenic differentiation of MG63 cells in vitro . (A) ALP activity assay of MG63 cells 24, 48 and 72 h post-transfection. (B) Quantitative real-time PCR analysis of SP7 , Runx2 and ColI mRNA levels 72 h post-transfection. (C and D) Western blot analysis (quality in C and quantity in D) of SP7, Runx2 and ColI protein levels 72 h post-transfection. Data represent the means ± SD of three independent experiments. * P < 0.05 vs. the blank group by paired t -test, # P < 0.05 vs. Lipofectamine 2000/miR-34a group by paired t -test.

Journal: RSC Advances

Article Title: N -Acetyl- l -leucine-polyethylenimine-mediated miR-34a delivery improves osteogenesis and bone formation in vitro and in vivo

doi: 10.1039/c7ra12548h

Figure Lengend Snippet: Osteogenic differentiation of MG63 cells in vitro . (A) ALP activity assay of MG63 cells 24, 48 and 72 h post-transfection. (B) Quantitative real-time PCR analysis of SP7 , Runx2 and ColI mRNA levels 72 h post-transfection. (C and D) Western blot analysis (quality in C and quantity in D) of SP7, Runx2 and ColI protein levels 72 h post-transfection. Data represent the means ± SD of three independent experiments. * P < 0.05 vs. the blank group by paired t -test, # P < 0.05 vs. Lipofectamine 2000/miR-34a group by paired t -test.

Article Snippet: The particle sizes and zeta potentials of N -Ac- l -Leu-PEI/miR-34a nanocomplexes were examined using a Zetasizer Nano ZS90 (Malvern Instruments, Malvern, UK).

Techniques: In Vitro, ALP Activity Assay, Transfection, Real-time Polymerase Chain Reaction, Western Blot

Bone formation in vivo in a cranial bone defect model. (A) CBCT image and micro-CT analysis 12 weeks post-implantation. (B) Quantitative analysis of micro-CT new bone formation data in the bone defect area by Image-Pro Plus software. (a) blank, (b) Lipofectamine 2000/miR-34a, (c) N -Ac- l -Leu-PEI/miR-34a. (C) Quantitative real-time PCR analysis of SP7 , Runx2 and ColI mRNA levels in the cranial defect area 12 weeks post-implantation. Data represent the means ± SD of three independent experiments. * P < 0.05 vs. the blank group by paired t -test, # P < 0.05 vs. Lipofectamine 2000/miR-34a group by paired t -test.

Journal: RSC Advances

Article Title: N -Acetyl- l -leucine-polyethylenimine-mediated miR-34a delivery improves osteogenesis and bone formation in vitro and in vivo

doi: 10.1039/c7ra12548h

Figure Lengend Snippet: Bone formation in vivo in a cranial bone defect model. (A) CBCT image and micro-CT analysis 12 weeks post-implantation. (B) Quantitative analysis of micro-CT new bone formation data in the bone defect area by Image-Pro Plus software. (a) blank, (b) Lipofectamine 2000/miR-34a, (c) N -Ac- l -Leu-PEI/miR-34a. (C) Quantitative real-time PCR analysis of SP7 , Runx2 and ColI mRNA levels in the cranial defect area 12 weeks post-implantation. Data represent the means ± SD of three independent experiments. * P < 0.05 vs. the blank group by paired t -test, # P < 0.05 vs. Lipofectamine 2000/miR-34a group by paired t -test.

Article Snippet: The particle sizes and zeta potentials of N -Ac- l -Leu-PEI/miR-34a nanocomplexes were examined using a Zetasizer Nano ZS90 (Malvern Instruments, Malvern, UK).

Techniques: In Vivo, Micro-CT, Software, Real-time Polymerase Chain Reaction

Journal: Journal of Biomedical Science

Article Title: EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex

doi: 10.1186/s12929-014-0108-9

Figure Lengend Snippet: Schematic showing the cell specific silencing strategy mediated by PEI nanocomplex fabricated with aptamer and siRNA. PEI nanoparticle is formed using sodium citrate as charge stabilizer, followed by the addition of siRNA and EpCAM aptamer to form the PEI-Apt-siRNA complex. This complex guided by the aptamer, binds to the EpCAM positive cells and delivers the siRNA in the cytoplasm resulting in target gene silencing and inhibition of cellular function pertained to it.

Article Snippet: PEI nanocomplex has been efficiently used for the delivery of siRNA using target specific antibody or affibody or aptamer.

Techniques: Inhibition, Cell Function Assay

Journal: Journal of Biomedical Science

Article Title: EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex

doi: 10.1186/s12929-014-0108-9

Figure Lengend Snippet: Effect of citrate on the nanocomplex size, charge and characterization of the nanocomplex. Graph showing the hydrodynamic sizes (A) and surface charge (B) of PEI: citrate nanocomplexes formed using different ratio of PEI to citrate measured using zetasizer. C . Titration of different concentration of aptamer and siRNA was carried out and loaded onto 2% agarose gel with ethidium bromide and checked for the retention of the PEI complex on the wells. Lane 3 shows 200nM of aptamer and 200nM of siRNA is required to saturate 0.3μgs of PEI and the next highest concentration of 300nM of aptamer & siRNA respectively had some amount of free siRNA and aptamer (lane 4). Lane 5 & 6 indicates free aptamer and siRNA indicated with red and black arrow respectively. On the right, histogram plot showing Particle size distribution of the PEI-Apt-siRNA nanocomplex. D . Histogram overlay plot showing the percent number distribution of the PEI nanocore alone and PEI-nanocomplex with aptamer and siRNA (hydrodynamic diameter in nm) measured using zetasizer. E . Graph showing the total counts of representative zeta-potential (mV) of the PEI nanocore and the PEI-Apt-siEp nanocomplex. F . TEM images of the PEI nanocomplex left panel showing the uniformity of particle distribution and histogram showing distinct particles with a spherical shape (G) . H . Graph showing the percentage cell proliferation upon treating with different concentration from 0.1 to 3 μg/mL of PEI on MCF-7 and WERI-Rb1 cell line till 48 h. Inhibitory effect of PEI on the cell proliferation and mitrochondrial activity was assessed by MTT assay.

Article Snippet: PEI nanocomplex has been efficiently used for the delivery of siRNA using target specific antibody or affibody or aptamer.

Techniques: Titration, Concentration Assay, Agarose Gel Electrophoresis, Zeta Potential Analyzer, Activity Assay, MTT Assay

Journal: Journal of Biomedical Science

Article Title: EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex

doi: 10.1186/s12929-014-0108-9

Figure Lengend Snippet: Cell Uptake of the PEI nanocomplex by MCF-7 and WERI-Rb1 cells. The fabricated PEI complexes and free aptamer were added to MCF-7 cells (upper panel A - E ), WERI-Rb1 cells (lower panel A - E ) and incubated for their uptake at 37°C for 4 h followed DAPI counterstaining and microscopic evaluation. Images were taken at 40× using AxioObserver fluorescent microscope. Legend on the top of phase image represents the aptamer or nanocomplex added to the respective panels.

Article Snippet: PEI nanocomplex has been efficiently used for the delivery of siRNA using target specific antibody or affibody or aptamer.

Techniques: Incubation, Microscopy

Schematic representation of DOX loading and BCL2 siRNA binding with the tumor targeting co-delivery nanocarrier (FA-HP-β-CD-PEI) for forming nanocomplexes to overcome MDR and enhance apoptosis in MCF-7/Adr tumor cells. Abbreviations: DOX, doxorubicin; siRNA, small interfering RNA; mRNA, messenger RNA; MDR, multidrug resistance; FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine; RISC, RNA-induced silencing complex.

Journal: International Journal of Nanomedicine

Article Title: Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier

doi: 10.2147/IJN.S67146

Figure Lengend Snippet: Schematic representation of DOX loading and BCL2 siRNA binding with the tumor targeting co-delivery nanocarrier (FA-HP-β-CD-PEI) for forming nanocomplexes to overcome MDR and enhance apoptosis in MCF-7/Adr tumor cells. Abbreviations: DOX, doxorubicin; siRNA, small interfering RNA; mRNA, messenger RNA; MDR, multidrug resistance; FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine; RISC, RNA-induced silencing complex.

Article Snippet: Comparing all the treatment groups, the FA-HP-β-CD-PEI/DOX/siRNA nanocomplexes showed the best cell apoptosis results (more than 70%), demonstrating the increased efficacy of DOX when combining siRNA BCL2 gene silencing by a codelivery nanocarrier.

Techniques: Binding Assay, Small Interfering RNA

Characterization of FA-HP-β-CD-PEI/DOX/siRNA FAM nanocomplexes by gel electrophoresis assay. Notes: The agarose gel electrophoresis showed the behavior of nanocomplexes with various N/P ratios (0, 1, 2, 4, 8, 16, and 32). When the N/P ratio was 16:1, the siRNA was retarded completely, and this N/P ratio was used in the following experiments. siRNA FAM Ex =488 nm, Em =535 nm, and the concentration was 100 nM. The gel was 1.5% and run for 10 minutes at 150 V. Abbreviations: DOX, doxorubicin; siRNA FAM , small interfering RNA link with FAM green fluorescent dye; FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine; Ex, excitation; Em, emission.

Journal: International Journal of Nanomedicine

doi: 10.2147/IJN.S67146

Figure Lengend Snippet: Characterization of FA-HP-β-CD-PEI/DOX/siRNA FAM nanocomplexes by gel electrophoresis assay. Notes: The agarose gel electrophoresis showed the behavior of nanocomplexes with various N/P ratios (0, 1, 2, 4, 8, 16, and 32). When the N/P ratio was 16:1, the siRNA was retarded completely, and this N/P ratio was used in the following experiments. siRNA FAM Ex =488 nm, Em =535 nm, and the concentration was 100 nM. The gel was 1.5% and run for 10 minutes at 150 V. Abbreviations: DOX, doxorubicin; siRNA FAM , small interfering RNA link with FAM green fluorescent dye; FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine; Ex, excitation; Em, emission.

Techniques: Nucleic Acid Electrophoresis, Agarose Gel Electrophoresis, Concentration Assay, Small Interfering RNA

TEM images and DLS measure of drug-loaded nanocomplexes. Notes: ( A ) TEM imaging of FA-HP-β-CD-PEI/DOX nanocomplexes; ( B ) TEM imaging of FA-HP-β-CD-PEI/DOX/siRNA nanocomplexes; ( C ) DLS of FA-HP-β-CD-PEI/DOX nanocomplexes; ( D ) DLS of FA-HP-β-CD-PEI/DOX/siRNA nanocomplexes. The N/P ratio was 16:1, and the concentration of siRNA was 100 nM. The scale bar 500 nm ( A , B ). Abbreviations: TEM, transmission electron microscopy; DLS, dynamic light scattering; DOX, doxorubicin; siRNA, small interfering RNA; FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine.

Journal: International Journal of Nanomedicine

doi: 10.2147/IJN.S67146

Figure Lengend Snippet: TEM images and DLS measure of drug-loaded nanocomplexes. Notes: ( A ) TEM imaging of FA-HP-β-CD-PEI/DOX nanocomplexes; ( B ) TEM imaging of FA-HP-β-CD-PEI/DOX/siRNA nanocomplexes; ( C ) DLS of FA-HP-β-CD-PEI/DOX nanocomplexes; ( D ) DLS of FA-HP-β-CD-PEI/DOX/siRNA nanocomplexes. The N/P ratio was 16:1, and the concentration of siRNA was 100 nM. The scale bar 500 nm ( A , B ). Abbreviations: TEM, transmission electron microscopy; DLS, dynamic light scattering; DOX, doxorubicin; siRNA, small interfering RNA; FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine.

Techniques: Imaging, Concentration Assay, Transmission Assay, Electron Microscopy, Small Interfering RNA

The release behavior of the DOX from the DOX-loaded nanocomplexes in different pH conditions (pH 5.0 and pH 7.4). Notes: When the DOX-loaded nanocomplexes were in the normal pH condition (pH 7.4), the DOX released from the nanocomplexes very slowly, and compared to the normal pH condition, the DOX released very quickly at pH 5.0 from the nanocomplexes, showing that the release of the DOX from the nanocarrier can be controlled by pH. DOX concentration of 0.5 μg/mL. Abbreviations: DOX, doxorubicin; siRNA, small interfering RNA; FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine.

Journal: International Journal of Nanomedicine

doi: 10.2147/IJN.S67146

Figure Lengend Snippet: The release behavior of the DOX from the DOX-loaded nanocomplexes in different pH conditions (pH 5.0 and pH 7.4). Notes: When the DOX-loaded nanocomplexes were in the normal pH condition (pH 7.4), the DOX released from the nanocomplexes very slowly, and compared to the normal pH condition, the DOX released very quickly at pH 5.0 from the nanocomplexes, showing that the release of the DOX from the nanocarrier can be controlled by pH. DOX concentration of 0.5 μg/mL. Abbreviations: DOX, doxorubicin; siRNA, small interfering RNA; FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine.

Techniques: Concentration Assay, Small Interfering RNA

Cell uptake of FA-HP-β-CD-PEI/DOX/siRNA FAM nanocomplexes was evaluated by CSLM ( A ) and FCM ( B ) in MCF-7/Adr cells. Notes: The free DOX, HP-β-CD-PEI/DOX/siRNA FAM , and free FA + FA-HP-β-CD-PEI/DOX/siRNA FAM were used as contrast. The tumor-targeting nanocomplexes showed the strongest fluorescence in the experiments. Incubation time, 4 hours; siRNA, 100 nM; DOX, 0.5 μg/mL; blue, Hoechst 33342, Ex 405 nm, Em 435 nm; green, siRNA FAM , Ex 488 nm, Em 535 nm; red, DOX, Ex 488 nm, Em 595 nm. Scale bars 40 μm ( A ). Abbreviations: FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine; DOX, doxorubicin; siRNA FAM , small interfering RNA link with FAM green fluorescent dye; CSLM, confocal scanning laser microscopy; FCM, flow cytometry; Ex, excitation; Em, emission.

Journal: International Journal of Nanomedicine

doi: 10.2147/IJN.S67146

Figure Lengend Snippet: Cell uptake of FA-HP-β-CD-PEI/DOX/siRNA FAM nanocomplexes was evaluated by CSLM ( A ) and FCM ( B ) in MCF-7/Adr cells. Notes: The free DOX, HP-β-CD-PEI/DOX/siRNA FAM , and free FA + FA-HP-β-CD-PEI/DOX/siRNA FAM were used as contrast. The tumor-targeting nanocomplexes showed the strongest fluorescence in the experiments. Incubation time, 4 hours; siRNA, 100 nM; DOX, 0.5 μg/mL; blue, Hoechst 33342, Ex 405 nm, Em 435 nm; green, siRNA FAM , Ex 488 nm, Em 535 nm; red, DOX, Ex 488 nm, Em 595 nm. Scale bars 40 μm ( A ). Abbreviations: FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine; DOX, doxorubicin; siRNA FAM , small interfering RNA link with FAM green fluorescent dye; CSLM, confocal scanning laser microscopy; FCM, flow cytometry; Ex, excitation; Em, emission.

Techniques: Fluorescence, Incubation, Small Interfering RNA, Microscopy, Flow Cytometry

Cell viability of drug-loaded nanocomplexes (HP-β-CD-PEI/DOX, HP-β-CD-PEI/siRNA, FA-HP-β-CD-PEI/DOX, FA-HP-β-CD-PEI/siRNA, HP-β-CD-PEI/DOX/siRNA, and FA-HP-β-CD-PEI/DOX/siRNA). Notes: Untreated cells and free DOX were controls. Concentrations of DOX and siRNA were 0.5 μg/mL and 100 nM, respectively. Treatment time was 48 hours. Abbreviations: FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine; DOX, doxorubicin; siRNA, small interfering RNA.

Journal: International Journal of Nanomedicine

doi: 10.2147/IJN.S67146

Figure Lengend Snippet: Cell viability of drug-loaded nanocomplexes (HP-β-CD-PEI/DOX, HP-β-CD-PEI/siRNA, FA-HP-β-CD-PEI/DOX, FA-HP-β-CD-PEI/siRNA, HP-β-CD-PEI/DOX/siRNA, and FA-HP-β-CD-PEI/DOX/siRNA). Notes: Untreated cells and free DOX were controls. Concentrations of DOX and siRNA were 0.5 μg/mL and 100 nM, respectively. Treatment time was 48 hours. Abbreviations: FA, folic acid; HP-β-CD, hydroxypropyl-β-cyclodextrin; PEI, polyethylenimine; DOX, doxorubicin; siRNA, small interfering RNA.

Techniques: Small Interfering RNA

Review

Structured Review

Images

1) Product Images from "EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex"

Similar Products

Image Search Results